An accelerated atherosclerosis may occur in the native arteries of a transplant recipient as well as in arteries of transplanted kidneys or hearts. The dominating cause of patient mortality are cardiovascular diseases, where ischaemic heart disease is predominant. The accelerated form of arteriosclerosis which takes place in transplanted kidneys and hearts, has a complex pathogenesis, which includes both immunological and non-
Introduction
An accelerated form of vascular intimal hyperplasia and atherosclerosis is a major limitation in organ transplantation. It may appear as a rapidly progressive atherosclerosis in the native arteries of a transplant patient leading to high incidence of ischaemia heart disease, cerebral vascular lesions or peripheral vascular complications. [1] [2] [3] This is the case in renal as well as heart transplant patients. Myocardial infarction is one of the most serious clinical manifestations hereof and has been shown to occur 3-35 times more frequently in a renal transplant population compared with an age and sex-matched control population. 4 The subgroup of patients who have the highest risk of a fatal myocardial infarction are male diabetic patients, aged 45-55 years, who have received a cadaveric kidney graft. 4 Furthermore, there is a great variability in ischaemic heart disease in the renal transplant population since the incidence is 3-5 times higher in northern Europe compared with southern Europe. 1, 2 The other manifestation of rapidly progressive vascular intimal hyperplasia and atherosclerosis strikes the transplanted organ, in particular kidneys and hearts. The manifestation consists of an obliteration of arteries and arterioles of transplanted kidney and in coronary arteries in transplanted hearts in conjunction with a deterioration of graft function. This is also called chronic rejection (CVR) or chronic transplant dysfunction, which is considered to be one of the leading causes of long-term failure of transplanted hearts and kidneys. [5] [6] [7] [8] It has been estimated from various investigations that there is a 3-4% annual loss of transplanted kidneys due to chronic rejection Ͼ1 year post-transplantation. In 
Pathogenesis and risk factors
The pathogenesis of accelerated atherosclerosis in native vessels of transplant recipients is not fully understood and there seems to be a complex mixture of several risk factors which are operative. Some of the risk factors that have been identified are hyperlipidaemia, diabetes, hypertension, smoking and acute rejection as well as the use of immunosuppressive agents to prevent acute rejection. 3 Male gender seems more susceptible than female gender. Renal transplant patients have an enhanced hyperlipidaemia, following transplantation, including total cholesterol and triglycerides. [9] [10] [11] Hypercholesterolaemia has been associated with the use of cyclosporin and hypertriglyceridaemia with the use of glucocorticoid treatment to prevent rejection. Tacrolimus, on the other hand, does not seem to lead to the same increase in cholesterol as cyclosporin. Diabetes is a clear-cut risk factor for myocardial infarction following renal transplantation. Apart from 25-30% of patients subjected to renal transplantation due to diabetes nephropathy, diabetes may also occur following transplantation, due to the negative effect of corticosteroids upon peripheral glucose tolerance. Hypertension has not been clearly demonstrated to be a risk factor per se for atherosclerosis in native vessels in the transplant recipient, which could be explained by the fact that the majority of the patients have hypertension and are on treatment with antihypertensive drugs.
One aspect which has not been so much studied in organ transplantation is the importance of endothelial cell dysfunction. A deficient endothelial function is by definition associated with deficient release of nitric oxide (NO), which has vasodilatory and antiproliferative characteristics. Endothelial dysfunction may be induced by hypertension, hyperlipidaemia and cyclosporin in transplanted patients. Furthermore, it has been suggested in heart transplant patients that auto-antibodies against certain epitopes of the endothelial cell may occur, in particular in patients who later develop chronic transplant dysfunction. 12 In renal transplant patients with deficient graft function and preuraemia it can also be anticipated that endothelial dysfunction is induced by the same mechanisms as in other cases with preuraemia. 13 To what extent it is true in transplant recipients still has to be shown, however.
The pathogenesis of graft arteriosclerosis is a combination of immunological and non-immunological factors. 5, 6, 14 The alloreaction participates in the development of CVR mainly through activated monocytes and macrophages. These cells have the ability to synthesise and secrete both cytokines and more specifically growth factors, which act upon smooth muscle cells and fibroblasts by stimulating proliferation and synthesis of connective tissue proteins. These events will propel the CVR process. Several studies have demonstrated a strong relationship between acute rejection episodes and subsequent development of CVR. It seems that both the number of acute rejection episodes and the type of acute rejection (AR) play a role, since acute vascular rejections have a larger propensity to lead to CVR than acute interstitial rejections. Furthermore, late AR also lead to higher risk for subsequent development of CVR. 15, 16 The degree of reversal of an AR has a strong influence upon the late outcome. It has recently been demonstrated that if an AR in a renal transplant is completely reversed and renal function recovered to the same level as before the AR there is apparently no increased propensity for late transplant failure in the picture of CVR. This seems to be irrespective of the means for treatment of the AR episodes. Several non-immunological risk factors have been identified to have an impact on the CVR process as well. These factors include ischaemiareperfusion damage, 17, 18 hypercholesterolaemia, [19] [20] [21] hypertension (see below) and obesity. Cytomegalovirus (CMV) infection has been shown in experimental models of CVR 22 and in heart transplantation to influence late development of CVR. A reduced renal mass due to previous AR may also cause hyperfiltration and a continued deterioration of the glomerulus according to the Brenner hypothesis. 23, 24 Immunological and non-immunological risk factors will act through molecular mediators including cytokines, growth factors and unregulated adhesion molecules to propel the CVR process. Growth factors that have been shown to be of importance for the development of CVR include platelet-derived growth factor (PDGF), 25, 26 transforming growth factor beta-1 (TGF-␤1) 27 and insulin-like growth factor-1 (IGF-1). A reduced NO release from endothelial cells following damage to the cell, oxidatively modified low-density lipoprotein (LDL) cholesterol and vasoactive peptides are also potential mediators of the CVR process. As a consequence cellular events will occur, which include smooth muscle cell migration into the intima and proliferation, fibroblast proliferation and an increased formation and deposition of extracellular matrix proteins. 7 These events will eventually lead to long-term deterioration of graft function, designated CVR.
Hypertension and accelerated atherosclerosis
Hypertension is a common feature in the renal transplant patient, necessitating treatment with antihypertensive drugs. 28 Hypertension is more common in the cyclosporin era compared with the era when patients were treated with steroids and azathioprine. Some of the causes of hypertension in renal transplantation are listed in Table 1 . The dominating causes of hypertension are due to diseases in the renal transplant, including acute rejection, chronic rejection, chronic cyclosporin nephrotoxicity, renal atherosclerosis and recurrency of renal disease. Cyclosporin treatment also contributes through induction of a vasoconstriction. This occurs partly through a direct vasoconstrictive effect upon smooth muscle cells (SMC), but also by an increase in the sensitivity to vasoconstrictors such as angiotensin-II, noradrenaline, vasopressin and endothelin-1. However, cyclosporin also has an adverse effect upon endothelial cell function leading to reduced secretion of NO and prostacyclin (PGI 2 ) and an increased secretion of endothelin-1. Not only is the synthesis of PGI 2 and PGE 2 reduced, but the synthesis of thromboxane is also increased by cyclosporin. Diseases in the native kidneys with enhanced output of renin also plays a role in some cases, necessitating nephrectomy of native kidneys.
There are many pathways by which hypertension may lead to a progressive graft atheriosclerosis almost irrespective of the cause of hypertension. One mechanism is through the effects on endothelial function by sheer stress, leading to an upregulation of growth factor mRNA in the endothelium, including PDGF and endothelin-1. Furthermore, sheer stress leads to a reduced secretion of NO, a potent vasodilator and inhibitor of smooth muscle cell proliferation. Growth factors released from the endothelium may act upon smooth muscle cells as well as mesangial cells leading to proliferation of the cells. It is also known from the literature that vasoconstrictors, such as angiotensin-II, endothelin-1 and thromboxane-A2, may stimulate to proliferation of smooth muscle cells, either directly or acting in synergy with growth factors (Figure 1 ). It has been claimed that pretransplant and posttransplant hypertension is a major risk factor for chronic renal transplant dysfunction [28] [29] [30] [31] [32] [33] since patients with deteriorating graft function had a higher level of treatment with antihypertensive drugs. 29 Hypertension was also recently suggested to be an independent risk factor for chronic graft failure, 34 based upon a multivariate analysis of posttransplant blood pressure and long-term kidney graft outcome. Whether hypertension is a risk factor independent of renal transplant function at baseline (baseline was patients with a functioning graft at 1, 3 or 5 years following transplantation) could not be concluded from this study, however, since transplant function at baseline was not included in the analysis. Such a dependence cannot be excluded, since blood pressure is largely dependent upon renal function.
Whether an intensified treatment of hypertension in renal transplant recipients with a reduced function may lead to reduced progression rate is still an open question. Based upon studies in a model of chronic rejection in the rat treatment with an ACE inhibitor may slow down the progression rate. 35 This is probably due to a reduction of the glomerular filtration pressure, which is most likely increased in cases with a reduced renal mass. 23, 24 On the other hand, ACE inhibitor is not the drug of choice in cyclosporin-induced hypertension, where there is mainly a vasoconstriction of the afferent arterioles. In these cases treatment with calcium channel blockers is more likely to be effective.
